New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - gabapentin 800mg; gabapentin 800mg - film coated tablet - 800 mg - active: gabapentin 800mg excipient: candelilla wax crospovidone magnesium stearate maize starch nitrogen opacode orange ns-78-13026 opadry white ys-1-18111 poloxamer 407 purified water active: gabapentin 800mg excipient: candelilla wax crospovidone magnesium stearate maize starch nitrogen opadry white ys-1-18111 poloxamer 407 purified water - neurontin is indicated for the treatment of partial seizures with or without secondarily generalised tonic-clonic seizures, in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs

Singapor - Ingliż - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - esomeprazole - injection, powder, for solution - 40 mg - esomeprazole 40 mg

Singapor - Ingliż - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - esomeprazole magnesium trihydrate 22.3mg eqv esomeprazole - tablet, film coated - 20 mg - esomeprazole magnesium trihydrate 22.3mg eqv esomeprazole 20 mg

Singapor - Ingliż - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - esomeprazole magnesium trihydrate 44.5mg eqv esomeprazole - tablet, film coated - 40 mg - esomeprazole magnesium trihydrate 44.5mg eqv esomeprazole 40 mg

Singapor - Ingliż - HSA (Health Sciences Authority)

zuellig pharma pte. ltd. - candesartan cilexetil; hydrochlorothiazide - tablet - 16 mg - candesartan cilexetil 16 mg; hydrochlorothiazide 12.5 mg

Singapor - Ingliż - HSA (Health Sciences Authority)

zuellig pharma pte. ltd. - candesartan cilexetil - tablet - 16 mg - candesartan cilexetil 16 mg

Singapor - Ingliż - HSA (Health Sciences Authority)

zuellig pharma pte. ltd. - candesartan cilexetil - tablet - 8 mg - candesartan cilexetil 8 mg

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - fludrocortisone acetate - tablet - 0.1 milligram(s) - mineralocorticoids; fludrocortisone - for partial replacement therapy for primary adrenocortical insufficiency in addison’s disease and for the treatment of salt-losing adrenogenital syndrome.

Unjoni Ewropea - Ingliż - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - tolvaptan - polycystic kidney, autosomal dominant - diuretics, - jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (adpkd) in adults with ckd stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.

Unjoni Ewropea - Ingliż - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cystic fibrosis - other respiratory system products - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4.4 and 5.1).in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5.1).kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4.4 and 5.1).in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.